These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
349 related articles for article (PubMed ID: 20445015)
61. Design and early clinical evaluation of selective inhibitors of monoamine oxidase. Palfreyman MG; McDonald IA; Bey P; Schechter PJ; Sjoerdsma A Prog Neuropsychopharmacol Biol Psychiatry; 1988; 12(6):967-87. PubMed ID: 3266532 [TBL] [Abstract][Full Text] [Related]
62. Limited potentiation of blood pressure response to oral tyramine by brain-selective monoamine oxidase A-B inhibitor, TV-3326 in conscious rabbits. Weinstock M; Gorodetsky E; Wang RH; Gross A; Weinreb O; Youdim MB Neuropharmacology; 2002 Nov; 43(6):999-1005. PubMed ID: 12423669 [TBL] [Abstract][Full Text] [Related]
63. Evaluation of the safety and tolerability of rasagiline in the treatment of the early stages of Parkinson's disease. Viallet F; Pitel S; Lancrenon S; Blin O Curr Med Res Opin; 2013 Jan; 29(1):23-31. PubMed ID: 23176073 [TBL] [Abstract][Full Text] [Related]
64. Inhibition of monoamine oxidase by moclobemide: effects on monoamine metabolism and secretion of anterior pituitary hormones and cortisol in healthy volunteers. Koulu M; Scheinin M; Kaarttinen A; Kallio J; Pyykkö K; Vuorinen J; Zimmer RH Br J Clin Pharmacol; 1989 Feb; 27(2):243-55. PubMed ID: 2469451 [TBL] [Abstract][Full Text] [Related]
65. Tyramine kinetics and pressor sensitivity during monoamine oxidase inhibition by selegiline. Schulz R; Antonin KH; Hoffmann E; Jedrychowski M; Nilsson E; Schick C; Bieck PR Clin Pharmacol Ther; 1989 Nov; 46(5):528-36. PubMed ID: 2510962 [TBL] [Abstract][Full Text] [Related]
66. Dopamine D2 receptor gene variants and response to rasagiline in early Parkinson's disease: a pharmacogenetic study. Masellis M; Collinson S; Freeman N; Tampakeras M; Levy J; Tchelet A; Eyal E; Berkovich E; Eliaz RE; Abler V; Grossman I; Fitzer-Attas C; Tiwari A; Hayden MR; Kennedy JL; Lang AE; Knight J; Brain; 2016 Jul; 139(Pt 7):2050-62. PubMed ID: 27190009 [TBL] [Abstract][Full Text] [Related]
67. (R)(+)-N-propargyl-1-aminoindan (rasagiline) and derivatives: highly selective and potent inhibitors of monoamine oxidase B. Sterling J; Veinberg A; Lerner D; Goldenberg W; Levy R; Youdim M; Finberg J J Neural Transm Suppl; 1998; 52():301-5. PubMed ID: 9564630 [TBL] [Abstract][Full Text] [Related]
68. Monoamine oxidase-B inhibitors in the treatment of Parkinson's disease: clinical-pharmacological aspects. Riederer P; Müller T J Neural Transm (Vienna); 2018 Nov; 125(11):1751-1757. PubMed ID: 29569037 [TBL] [Abstract][Full Text] [Related]
69. Monoamine oxidase-B inhibition in the treatment of Parkinson's disease. Fernandez HH; Chen JJ Pharmacotherapy; 2007 Dec; 27(12 Pt 2):174S-185S. PubMed ID: 18041937 [TBL] [Abstract][Full Text] [Related]
70. Rasagiline: time to onset of antiparkinson effect is similar when used as a monotherapy or adjunct treatment. Wilson RE; Seeberger LC; Silver D; Griffith A; Conner JB; Salzman PM; Neurologist; 2011 Nov; 17(6):318-24. PubMed ID: 22045282 [TBL] [Abstract][Full Text] [Related]
71. Rasagiline, a suicide inhibitor of monoamine oxidases, binds reversibly to α-synuclein. Kakish J; Tavassoly O; Lee JS ACS Chem Neurosci; 2015 Feb; 6(2):347-55. PubMed ID: 25514361 [TBL] [Abstract][Full Text] [Related]
72. Pharmacokinetic-pharmacodynamic interactions between two selective monoamine oxidase inhibitors: moclobemide and selegiline. Dingemanse J; Kneer J; Wallnöfer A; Kettler R; Zürcher G; Koulu M; Korn A Clin Neuropharmacol; 1996 Oct; 19(5):399-414. PubMed ID: 8889283 [TBL] [Abstract][Full Text] [Related]
73. Safety comparisons among monoamine oxidase inhibitors against Parkinson's disease using FDA adverse event reporting system. Asano H; Tian YS; Hatabu A; Takagi T; Ueda M; Ikeda K Sci Rep; 2023 Nov; 13(1):19272. PubMed ID: 37935702 [TBL] [Abstract][Full Text] [Related]
74. The effect of safinamide, a novel drug for Parkinson's disease, on pressor response to oral tyramine: a randomized, double-blind, clinical trial. Marquet A; Kupas K; Johne A; Astruc B; Patat A; Krösser S; Kovar A Clin Pharmacol Ther; 2012 Oct; 92(4):450-7. PubMed ID: 22948897 [TBL] [Abstract][Full Text] [Related]
75. A new formulation of selegiline: improved bioavailability and selectivity for MAO-B inhibition. Clarke A; Brewer F; Johnson ES; Mallard N; Hartig F; Taylor S; Corn TH J Neural Transm (Vienna); 2003 Nov; 110(11):1241-55. PubMed ID: 14628189 [TBL] [Abstract][Full Text] [Related]
76. Modification of blood pressure and nictitating membrane response to sympathetic amines by selective monoamine oxidase inhibitors, types A and B, in the cat. Finberg JP; Youdim MB Br J Pharmacol; 1985 Jun; 85(2):541-6. PubMed ID: 3928010 [TBL] [Abstract][Full Text] [Related]
77. Effect of rasagiline as adjunct therapy to levodopa on severity of OFF in Parkinson's disease. Stocchi F; Rabey JM Eur J Neurol; 2011 Dec; 18(12):1373-8. PubMed ID: 21895884 [TBL] [Abstract][Full Text] [Related]
78. Neuroprotective profile of the multitarget drug rasagiline in Parkinson's disease. Weinreb O; Amit T; Riederer P; Youdim MB; Mandel SA Int Rev Neurobiol; 2011; 100():127-49. PubMed ID: 21971006 [TBL] [Abstract][Full Text] [Related]